Atea Q1 2023 financial report and presentation
Atea reported another consecutive quarter of strong sales growth, record profits and solid cash flow from operations in Q1 2023.
…
136,890NOK
-6,41%
Echtzeit-Aktienkurs Atea ASA
Bid:
Ask:
Nachrichten zur Atea ASA Aktie
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…
Presentation of 1[st] quarter 2023 results
Atea ASA will present its 1[st] quarter 2023 financial results on Thursday, 27 April 2023 at 08:00 CEST.
The presentation will…
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study,…
Atea ASA 2022 Annual Report in ESEF format
The company publishes its annual financial statements in European Single
Electronic Format (ESEF), available as an attachment to this release.
Compared to…
Notice of Annual General Meeting
The Annual General Meeting will be held on Thursday 27 April 2023 at 09:30 a.m. at Thon Hotel Vika Atrium,…
Key information relating to cash dividend to be paid by Atea ASA
The Board of Atea ASA has proposed a cash dividend with the following key details:
Dividend amount: …
Atea Norway signs large public sector frame agreement
Atea has today signed a large public sector frame agreement with the Norwegian state procurement authority (DFØ). The frame agreement…
Grant of share options to primary insiders in Atea ASA
On 16 March 2023, key employees in the Atea Group were granted share options in Atea ASA.
The following primary insiders…
Chairman Ib Kunøe to step down from Board
Chairman Ib Kunøe has notified his intention to retire from the Board of Directors of Atea ASA following the Annual…
GlobalConnect appoints Annette Otto as SVP of People and Culture
Nordic digital infrastructure and connectivity provider GlobalConnect appoints Annette Otto as its new SVP of People and Culture. Otto comes…
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged…
Form 10-K Atea Pharmaceuticals, For: Dec 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Atea Pharmaceuticals GAAP EPS of -$0.41 beats by $0.04
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions...…
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections
BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today…
Atea Q4 2022 financial report and presentation
Atea reported very strong sales in all countries and across all lines of business during the fourth quarter, driving record…
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
BOSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today…
Presentation of 4[th] quarter 2022 results
Atea ASA will present its 4[th] quarter 2022 financial results on Thursday, 9 February 2023 at 08:00 CEST.
The presentation will…
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today…